Description: Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Home Page: www.hepionpharma.com
HEPA Technical Analysis
399 Thornall Street
Edison,
NJ
08837
United States
Phone:
732 902 4000
Officers
| Name | Title |
|---|---|
| Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. | Pres, CEO & Director |
| Mr. John T. Cavan | Chief Financial Officer |
| Dr. Todd M. Hobbs M.D. | Chief Medical Officer |
| Dr. Launa J. Aspeslet Ph.D. | Chief Operating Officer |
| Dr. Daren Ure Ph.D. | Chief Scientific Officer |
| Sharen Pyatetskaya | Director of Investor Relations |
| Dr. Daniel J. Trepanier Ph.D. | Sr. VP of Drug Devel. |
| Dr. Patrick R. Mayo Ph.D. | Sr. VP of Clinical Pharmacology |
| Dr. John Z. Sullivan-Bolyai | Part-Time Consultant |
| Dr. Stephen A. Harrison M.D. | Member of Scientific Advisory Board & Consultant Medical Director |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4172 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-02-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 20 |